Here, we report the first documented case of long-term remission in a patient with refractory acute myeloid leukemia (AML) after graft failure of allogeneic cord blood stem cells, and subsequent remission of AML, along with an expansion of autologous CD8
þ cytotoxic T cells. This 67-year-old Caucasian man developed progressive pancytopenias and was referred to our institution in August 2007. The patient's bone marrow aspirate revealed 43% blasts with morphology and an immunophenotype consistent with AML M4, according to the FAB (French-American-British) classification (see Figures 1a and b) . Cytogenetic and molecular tests showed a normal diploid karyotype, and the FLT3 mutation status was negative. His other significant past medical history included seronegative rheumatoid arthritis, and a history of prostate cancer, treated with radical prostatectomy. The patient's AML was initially treated with two courses of clofarabine between August and October 2007. However, he was found to be primary refractory to this treatment with persistent bone marrow blasts, accounting for 14% of marrow cellularity in November 2007. Therefore, the patient then received salvage treatment with three courses of idarubicin, cytarabine and X-linked inhibitor of apoptosis protein About 6-7 weeks after the CB-SCT, the patient gradually developed a lymphocytosis that is illustrated in Figure 2a . The lymphocytes were 100% of host origin by microsatellite polymorphism analysis, and they were oligoclonal CD8 þ T cells, as shown by the oligoclonal pattern of T-cell receptor g-chain gene rearrangements by PCR analysis and flow cytometry, respectively. Figure 2b illustrates the immunophenotype of the expanded T cells. Now, 16 months after his cord blood transplant, the patient has been without any evidence of leukemia both on peripheral blood and bone marrow tests, and Figure 1 Bone marrow morphology before (a, b) and after cord blood stem cell transplantation (c, d). Panels a and b depict bone marrow aspirate smears at the initial presentation with myeloblasts in a background of dysplastic erythroid and myeloid elements (Wright-Giemsa stains, photographed at Â 1000). Panels c and d display photomicrographs of bone marrow aspirate smears after cord blood stem cell transplantation (CB-SCT) that are consistent with a complete remission and that depict scattered large granular lymphocytes (black arrows) in a background of mildly dysplastic myeloid cells, some with hypogranular cytoplasm (blue arrow).
Letters to the Editor has been managed only with observation. Clinically, the patient has become fully asymptomatic and is doing very well over the course of the last year, and his arthritis, which was a (possibly paraneoplastic) major clinical issue at diagnosis, is also in remission.
The clinical course and laboratory studies in this case suggest that allogeneic cord blood cells triggered the oligoclonal expansion of autologous cytotoxic T cells that cross-react with the patient's AML clone. To our knowledge, this is the first case of a remission after an unsuccessful engraftment of CB-SCs, and therefore we will discuss these findings in the context of the graftversus-leukemia effect and spontaneous remission (SR) in AML.
SR is an infrequent but recurrent and often well-documented phenomenon in patients with renal cell carcinoma or malignant melanoma, but a rarity in cancers of the hematopoietic system. The published cases of SR in patients with AML indicate that this is an exceedingly rare and generally temporary event, with a mean remission duration of approximately 6-7 months.
1,2 The mechanism responsible for inducing these remissions is largely unknown, although the reported cases suggest that there may be a correlation with infections or blood transfusions. 3 It has been speculated that these events trigger immune responses responsible for SR. Natural killer cells and cytotoxic T cells transfused with blood products, or cytokines, such as tumor necrosis factor and interleukin-2, released during infections have been proposed to participate in the development of SR. Previous reports of successful reinduction of a second SR by BCG vaccination support the hypothesis that SR in AML is a T cell-mediated process. 4, 5 In hematopoietic SCT, the importance of T cellmediated immune responses for induction of remissions through the 'graft-versus-leukemia' effect is well established. 6 Furthermore, it is increasingly recognized that the induction of effective alloreactive T-cell responses against leukemia stem and progenitor cells is essential for complete eradication of AML after SCT. Several studies have shown a correlation between the presence of T cells recognizing leukemia CD34
þ progenitor cells and the occurrence of complete remissions in vivo. 7 Furthermore, distinct minor histocompatibility antigens expressed on AML progenitor cells, which are recognized by CD8 þ T cells, are emerging, and have been proposed as target antigens for immunotherapy. 8 In summary, we report the fascinating case of a primary refractory AML patient who achieved complete remission after an allogeneic SCT with graft failure, lasting now for more than 16 months. This remission coincided with the oligoclonal expansion of autologous CD8 þ T cells, suggesting that CB-SCT triggered the induction and expansion of autologous cytotoxic T cells that cross-react with the AML clone. This unique case illustrates that failure of a therapeutic intervention (here, the cord blood graft loss) can sometimes trigger events that benefit the patient, and also encourages our hopes that our immune system, if properly primed and targeted, has the capacity to overcome relapsed/refractory AML, clinically one of the most dismal settings. In Winston Churchill's words, 'Success is not final, failure is not fatal: it is the courage to continue that counts.' and anti-CD8mAbs, revealing that 83.3% of the lymphocytes were CD8 positive (center box). Staining with anti-CD57 and anti-CD94mAbs (righthand box) also revealed that these CD8
þ T cells displayed a phenotype consistent with large granular lymphocytes (LGLs), which is in keeping with the morphology of these activated lymphocytes (Figures 1c and d) .
